Overview of treatment diagnosis and of migraine

Neurology

Volumn 44, Issue 10, 1994, Pages 6-16

  Silberstein, Stephen D ^a   Lipton, Richard B ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC BETA ANTAGONISTS; ANTI INFLAMMATORY AGENTS, NON STEROIDAL; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROERGOTAMINE; ERGOTAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN ANTAGONIST; SUMATRIPTAN; TRICYCLIC ANTIDEPRESSANT AGENT;

HUMAN; MIGRAINE; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CALCIUM CHANNEL BLOCKERS; DIHYDROERGOTAMINE; ERGOTAMINE; HUMAN; MIGRAINE; SEROTONIN ANTAGONISTS; SUMATRIPTAN;

EID: 0028521134     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: None     Document Type: Article

References (98)

1. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. JAMA 1992;267: 64-69.
2. Lipton RB, Stewart WF. Migraine in the United States: epidemiology and health care utilization. Neurology 1993; 43(suppl 3):6-10.
3. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resources and lost labour costs of migraine headaches in the US. Pharmaco Economics 1992;2:67-76.
4. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993;33:29-35.
5. Lipton RB, Stewart W, Celentano DD, et al. Undiagnosed migraine: a comparison of symptom-based and self-reported physician diagnosis. Arch Intern Med 1992;156:1-6.
6. Celentano DD, Stewart WF, Lipton RB, et al. Medication use and disability among migraineurs: a national probability sample. Headache 1992;32:223-228.
7. Lipton RB, Amatniek J, Ferrari MD, et al. Migraine: identifying and removing barriers to care. Neurology 1994;44 (suppl 6):S56-S62.
8. Silberstein SD, Saper J. Migraine: diagnosis and treatment. In: Dalessio D, Silberstein SD, eds. Wolffs headache and other head pain. 6th ed. New York: Oxford University Press, 1993:96-170.
9. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia, and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
10. Blau JN. Migraine prodromes separated from the aura: complete migraine. Br Med J 1980;281:658-660.
11. Lance JW, Anthony M. Some clinical aspects of migraine. Arch Neurol 1966;15:356-361.
12. Wilkinson M. Clinical features of migraine. In: Rose FC, ed. Handbook of clinical neurology. New York: Elsevier, 1986: 117-133.
13. Hupp SL, Kline LB, Corbett JJ. Visual disturbances of migraine. Surv Ophthalmol 1989;33:221-236.
14. Hachinski VCC, Porchawka J, Steele JC. Visual symptoms in the migraine syndrome. Neurology 1973;23:570-579.
15. Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry 1960;23:23-32.
16. Silberstein SD, Silberstein MM. Clinical symptomatology and differential diagnosis. In: Tollison CD, Kunkel RS, eds. Headache: diagnosis and treatment. Baltimore: Williams & Wilkins, 1993:59.
17. Stewart WF, Schecter A, Lipton RB. Migraine heterogeneity: disability, pain intensity, attack frequency, and duration. Neurology 1994;44(suppl 4):S24-S39.
18. Drummond PD. A quantitative assessment of photophobia in migraine and tension headache. Headache 1986;26:465-469.
19. Olesen J, Lipton RB. Migraine classification and diagnosis according to the International Headache Society. Neurology 1994;44(suppl 4):S6.
20. Lipton RB, Silberstein SD, Stewart WF. An update on migraine epidemiology. Headache 1994;36:319-328.
21. Lipton RB, Stewart WF, Merikangas KR. Reliability in headache diagnosis. Cephalalgia 1993;13(suppl 12):29.
22. Granella E, D’Alessandro R, Mazoni GC, et al. International Headache Society classification: interobserver reliability in the diagnosis of primary headache disorders. Cephalalgia 1994;14:16-20.
23. Stewart WF, Lipton RB, Schecter A. Diagnostic criteria for migraine: a validity study. Neurology 1994;44(suppl 4):S11-S16.
24. Merikangas KR, Frances A. Development of diagnostic crite-ria for headache syndromes: lessons from psychiatry. Cephalalgia 1993;13(suppl 12):34-38.
25. Solomon S, Lipton RB, Newman LC. Evaluation of chronic daily headache comparison to criteria for chronic tension- type headache. Cephalalgia 1992;12:365-368.
26. Silberstein SD, Lipton R, Solomon S, et al. Classification of daily and near daily headaches: proposed revisions to the IHS classification. Headache 1994;34:1-7.
27. Pfaffenrath V, Isler H. Evaluation of the nosology of chronic tension-type headache. Cephalalgia 1993;13(suppl 12):60-62.
28. Rassmussen BK, Jensen R, Olesen J. A population-based analysis of the diagnostic criteria of the International Headache Society. Cephalalgia 1991;11:129-134.
29. Russell MB, Iversen HK, Olesen J. Improved description of the migraine aura by a diagnostic aura diary. Cephalalagia 1994;14:107-117.
30. Raskin NH. Headache. 2nd ed. New York: Churchill Livingstone, 1988.
31. Silberstein SD. Review: serotonin 5-HT and migraine. Headache 1994;34:408-417.
32. Humphrey PPA, Feniuk W, Perren MJ. Anti-migraine drugs in development: advances in serotonin receptor pharmacology. Headache 1990;30(suppl 1): 12.
33. Brewerton TD, Murphy DL, Mueller EA, et al. Induction of migraine-like headaches by the serotonin agonist m- chlorophenylpiperazine. Clin Pharmacol Ther 1988;43:605-609.
34. Gordon ML, Lipton RB, Brown S-L, et al. Headache and cortical responses to m-chlorophenylpiperazine are highly correlated. Cephalalgia 1993;13:400-405.
35. Peroutka SJ. Developments in 5-hydroxytryptamine receptor pharmacology in migraine. Neurol Clin 1990;8:829-838.
36. Peroutka SJ. The pharmacology of current antimigraine drugs. Headache 1990;30(suppl 1):12.
37. Callaham M, Raskin N. A controlled study of dihydroergot- amine in the treatment of acute migraine headache. Headache 1986;26:168-171.
38. Goadsby PJ, Gundlach AL. Localization of 3H-dihydroergot- amine-binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 1991;29:91-94.
39. Lance JW. The pharmacotherapy of migraine. Med J Aust 1986;144:85-88.
40. Tfelt-Hansen P, Lipton RB. Prioritizing treatment. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The headaches. New York: Raven Press, 1993:359-362.
41. Sawynok J, Yaksh TL. Caffeine as analgesic adjuvant: a review of pharmacology and mechanisms of action. Pharmacol Rev 1993;45:43-85.
42. Ryan RE. A study of Midrin in the symptomatic relief of migraine headache. Headache 1974;14:33-42.
43. Yuill GM, Swinburn WR, Liversedge LA. A double-blind crossover trial of isometheptene mucate compound and ergotamine in migraine. Br J Clin Pract 1972;26:76-79.
44. Tfelt-Hansen P, Lipton RB. Miscellaneous drugs. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The headaches. New York: Raven Press, 1993:353-358.
45. Wilkinson M. Treatment of migraine. Headache 1988;28: 659-661.
46. Olesen J, Aebelholt A, Veilis B. The Copenhagen acute headache clinic: organization, patient material, and treatment results. Headache 1979;19:223-227.
47. Lipton RB, Tfelt-Hansen P. Neuroleptics. In: Olesen J, Tfelt- Hansen P, Welch KMA, eds. The headaches. New York: Raven Press, 1993:349-352.
48. Bowdle TA, Galer BS. Agonist-antagonist and partial agonist opioids: pharmacologic mechanisms and clinical application in the treatment of headache. Headache Quarterly 1993;4:322-336.
49. Tfelt-Hansen P, Johnson ES. Nonsteroidal antiinflammatory drugs in the treatment of the acute migraine attack. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The headaches. New York: Raven Press, 1993:305-311.
50. Sanders SW, Haering N, Mosberg H, et al. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol 1986;30:331-334.
51. Volans GN. Research review: migraine and drug absorption.Clin Pharmacokinet 1978;3:313-318.
52. Silberstein SD. Twenty questions about headaches in children and adolescents. Headache 1990;30:716-724.
53. Kanto J, Allonen H, Koski K, et al. Pharmacokinetics of di- hydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. Int J Clin Pharmacol Ther Toxicol 1981;19:127-130.
54. Schran HF, Tse FLS. Pharmacokinetics of dihydroergot- amine following subcutaneous administration in humans. Int J Clin Pharmacol Ther Toxicol 1985;23:1-4.
55. Winner P, Sheftell F, Sadowsky C, et al. A profile of menstrual migraine sufferers. Cephalalgia 1993;13:242.
56. Sheftell F, Sadowsky C, Winner P, et al. Reduced incidence of nausea and vomiting after administration of dihydroer- gotamine mesylate (DHE 45) for acute migraine headache. Cephalalgia 1993;13:100.
57. Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. Headache 1990;30:334-339.
58. Silberstein SD, Silberstein JR. Chronic daily headache: long-term prognosis following inpatient treatment with repetitive IV DHE. Headache 1992;32:439-445.
59. Cady RK, Wendt JK, Kirehner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265: 2831-2835.
60. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-321.
61. Mathew NT, Dexter J, Couch J, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. Arch Neurol 1992;49:1271-1276.
62. Tansey MJB, Pilgrim AJ, Lloyd K. Sumatriptan in the acute treatment of migraine. J Neurol Sci 1993;114:109-116.
63. Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci 1993;14:129-133.
64. Dechant KL, Clissold SP. Sumatriptan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1992;43:776-798.
65. Hannington-Kiff JG. Sumatriptan relieves and prevents perioperative migraine attacks. Anaesthesia 1993;48:144-146.
66. Solbach MP, Waymer RS. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Obstet Gynecol 1993;82:769-772.
67. Bousser MG, d’Allens H, Richard A, et al. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. J Intern Med 1993;234:211-216.
68. The Oral Sumatriptan International Multiple-dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991;306-313.
69. Hillis WS, MacIntyre PD. Sumatriptan and chest pain. Lancet 1993;341:1564-1565.
70. Boyle R, Behan PO, Sutton JA. A correlation between severity of migraine and delayed emptying measured by an epigastric impedance method. Br J Clin Pharmacol 1990;30: 405-409.
71. Tfelt-Hansen P, Olesen J, Aebelholt-Krabbe A, et al. A double blind study of metoclopramide in the treatment of migraine attacks. J Neurol Neurosurg Psychiatry 1980;43:369-371.
72. Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med 1983;98:86-95.
73. Tfelt-Hansen P, Welch KMA. Prioritizing prophylactic treatment. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The headaches. New York: Raven Press, 1993:403-404.
74. Andersson K, Vinge E. a-Adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. Drugs 1990;39:355-373.
75. Weber RB, Reinmuth OM. The treatment of migraine with propranolol. Neurology 1972;22:366-369.
76. Markley HG, Gasser PA, Markley ME, et al. Fluoxetine in prophylaxis of migraine: clinical experience. Cephalalgia 1991;11(suppl 11):164-165.
77. Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache 1992;32:101-104.
78. Moskowitz MA. Basic mechanisms in vascular headache. Neurol Clin 1990;8:801-815.
79. Curran DA, Hinterberger H, Lance JW. Methysergide. Res Clin Stud Headache 1967;1:74-122.
80. Curran DA, Lance JW. Clinical trial of methysergide and other preparations in the management of migraine. J Neurol Neurosurg Psychiatry 1964;27:463-469.
81. Drummond PD. Effectiveness of methysergide in relation to clinical features of migraine. Headache 1985;25:145-146.
82. Elkind AH, Friedman AP, Bachman A, et al. Silent retroperitoneal fibrosis associated with methysergide therapy. JAMA 1968;206:1041-1044.
83. Graham J. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci 1967;254:1-12.
84. Barlow CF. Headaches and migraine in children. Philadelphia: Lippincott, 1984.
85. Forsythe I, Hockaday JM. Management of childhood migraine. In: Hockaday JM, ed. Migraine in childhood and other non-epileptic paroxysmal disorders. Boston: Butter- worths, 1988:63-74.
86. Peatfield R. Drugs acting by modification of serotonin function. In: Headache. Berlin: Springer-Verlag, 1986:129-131.
87. Capildeo R, Rose FC. Single-dose pizotifen, 1.5 mg nocte: a new approach in the prophylaxis of migraine. Headache 1982;22:272-275.
88. Prensky AL. Migraine in children. In: Blau JN, ed. Migraine: clinical and research aspects. Baltimore: Johns Hopkins University Press, 1987:31-53.
89. Raskin NH. Modern pharmacotherapy of migraine. Neurol Clin 1990;8:857-865.
90. Welch KMA, Chabi E, Bartosh K, et al. Cerebrospinal fluid gamma aminobutyric acid levels in migraine. Br Med J 1975;3:516-517.
91. Ferrari MD, Odnik J, Bos KD, et al. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 1990;40: 1582-1586.
92. Sorensen KV. Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand 1988;78:346-348.
93. Mathew NT. Valproate in the treatment of persistent chronic daily headache. Headache 1990;30:301.
94. Sianard-Gainko J, Lenaerts M, Bastings E, et al. Sodium valproate in severe migraine and tension-type headache: clinical efficacy and correlations with blood levels. Cephalalgia 1993;13:252.
95. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study vs placebo. Cephalalgia 1992;12:81-84.
96. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled, crossover study. Neurology 1994;44:647-651.
97. Silberstein SD, Saper J, Mathew N. The safety and efficacy of divalproex sodium in the prophylaxis of migraine headache: a multicenter, double-blind, placebo-controlled trial. Headache 1993;33:264-265.
98. Robert AH. Behavioral management of headache. In: Dalessio D, Silberstein SD, ed. Wolffs headache and other head pain. 6th ed. New York: Oxford University Press, 1993:483-501.